West Pharmaceutical Services, Inc. Common Stock (WST)
205.36
-5.62 (-2.66%)
NYSE · Last Trade: May 6th, 8:24 PM EDT
Detailed Quote
Previous Close
210.98
Open
210.24
Bid
179.79
Ask
242.29
Day's Range
204.78 - 210.85
52 Week Range
187.43 - 372.52
Volume
672,852
Market Cap
14.85B
PE Ratio (TTM)
32.24
EPS (TTM)
6.4
Dividend & Yield
0.8400 (0.41%)
1 Month Average Volume
1,079,710
Chart
About West Pharmaceutical Services, Inc. Common Stock (WST)
West Pharmaceutical Services is a prominent global leader in the design and manufacturing of components and systems for the delivery of injectable drugs. The company specializes in producing high-quality materials such as stoppers, seals, and prefillable syringes, which are essential for the safe and efficient administration of pharmaceuticals. West Pharmaceutical Services partners with pharmaceutical and biotechnology companies to deliver innovative solutions that enhance drug efficacy and patient safety, focusing on advancing healthcare through its cutting-edge technologies and services. With a commitment to excellence and a strong emphasis on sustainability, West continually strives to improve the standards of drug delivery within the healthcare industry. Read More
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Labaton Keller Sucharow LLP (“Labaton”) announces that, on May 5, 2025, it filed a securities class action lawsuit (the “Complaint”) on behalf of its client the New England Teamsters Pension Fund (“New England Teamsters”) against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and certain West executives (collectively, “Defendants”). The action, which is captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.) asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired West common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”).
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $698 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $1.45 per share was 18.1% above analysts’ consensus estimates.
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade tensions boosts risk sentiment.
Healthcare products company West Pharmaceutical Services (NYSE:WST)
will be reporting results tomorrow before market open. Here’s what investors should know.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
West Pharmaceutical Services has gotten torched over the last six months - since October 2024, its stock price has dropped 29.3% to $202.47 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
The S&P 500 is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.
